Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD
- Sponsor
- Incyte Corporation
- Study ID
- NCT05722912
- Status
- Approved For Marketing
Conditions
- Graft-versus-host Disease (GVHD)
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib — DRUGRuxolitinib Cream
Study Details
To provide ruxolitinib through an expanded access to treat a single patient with cGVHD
Key Dates
- Status verified
- Jan 2023
Related Studies
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)PHASE3 · Recruiting · Incyte Corporation · Palo Alto, California
- Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationPHASE2 · Recruiting · University of Nebraska · Omaha, Nebraska
- Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD PreventionPHASE2 · Recruiting · Milton S. Hershey Medical Center · Hershey, Pennsylvania